Star Equity Holdings And 2 Other Stocks Under $2 Insiders Are Aggressively Buying
Portfolio Pulse from Lisa Levin
Insiders at Aytu BioPharma, CURO Group Holdings, and Star Equity Holdings have recently made significant purchases of their respective companies' stocks. Aytu BioPharma announced a $4 million public offering, CURO Group posted a wider-than-expected quarterly loss, and Star Equity reported a profit for Q1.
June 16, 2023 | 11:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aytu BioPharma CEO Joshua R Disbrow acquired 14,000 shares at an average price of $1.86, following the announcement of a $4 million public offering.
The CEO's purchase of shares indicates confidence in the company's prospects, especially following the announcement of a $4 million public offering. This could lead to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
CURO Group Holdings Director Heath Chadwick Faulkner acquired 20,000 shares at an average price of $1.87, despite the company posting a wider-than-expected quarterly loss.
The director's purchase of shares, even after the company posted a wider-than-expected quarterly loss, indicates confidence in the company's future prospects. This could lead to a short-term positive impact on the stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Star Equity Holdings Executive Chairman Jeffrey E Eberwein acquired 47,221 shares at an average price of $1.18, following the company's Q1 profit report.
The executive chairman's purchase of shares indicates confidence in the company's performance, especially after reporting a profit for Q1. This could lead to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100